Health Economics›Multiple myeloma›Relapsed or refractory triplets

Relapsed or refractory triplets

Multiple myeloma · 39 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 22 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Dara-Kd Variant #01	—	R 846 276	28d	~28.5 mo	~50.8 mo	~31	~R 26 234 569 PFS proxy · indirect	3
Dara-Pd Variant #01	—	R 395 754	28d	~8.4 mo	—	~10	~R 3 957 543 PFS proxy · indirect	2
Dara-Rd Variant #01	—	R 372 680	28d	~53.2 mo	~67.6 mo	~58	~R 21 615 466 PFS proxy · indirect	6
SDd Variant #01 Partial	—	R 367 235	28d	—	—	—	—	—
Ven-Kd Variant #01	—	R 361 767	28d	—	—	—	—	—
Isa-Kd Variant #01 Partial	—	R 269 660	28d	~35.7 mo	—	~39	~R 10 516 727 PFS proxy · indirect	1
Dara-Vd Variant #01	—	R 214 267	28d	~10.6 mo	~49.6 mo	~12	~R 2 571 208 PFS proxy · indirect	6
SKd Variant #01 Partial	—	R 188 142	28d	—	—	—	—	—
KRd Variant #05	—	R 185 594	28d	~34.6 mo	~48.3 mo	~38	~R 7 052 582 PFS proxy · indirect	6
KPD Variant #03	—	R 168 358	28d	—	—	—	—	—
Dara-Kd (SC daratumumab) Variant #01 Partial	—	R 166 423	28d	—	—	—	—	—
IRd Variant #01	—	R 65 250	28d	~13.7 mo	~25.8 mo	~15	~R 978 745 PFS proxy · indirect	5
VTD Variant #10	—	R 46 769	42d	~35.8 mo	—	~26	~R 1 215 998 PFS proxy · indirect	1
CTD Variant #02	—	R 42 203	28d	—	—	—	—	—
BID Variant #01	—	R 37 908	28d	—	—	—	—	—
PCD Variant #03	—	R 29 642	28d	~10.9 mo	—	~12	~R 355 700 PFS proxy · indirect	1
Isa-Pd Variant #01 Partial	—	R 29 040	28d	~11.5 mo	~24.6 mo	~13	~R 377 516 PFS proxy · indirect	3
BPd Variant #01 Partial	—	R 29 040	28d	—	—	—	—	1
Dara-Pd (SC daratumumab) Variant #01 Partial	—	R 28 866	28d	~11.8 mo	—	~13	~R 375 259 PFS proxy · indirect	4
PVD Variant #03	—	R 26 054	21d	~11.8 mo	—	~18	~R 468 967 PFS proxy · indirect	5
PCP Variant #01	—	R 24 036	28d	—	—	—	—	—
VDC Variant #04	—	R 10 611	35d	~30.0 mo	—	~27	~R 286 501 PFS proxy · indirect	1
RVD Variant #01	—	R 10 486	28d	~43.0 mo	—	~47	~R 492 828 PFS proxy · indirect	9
BTD Variant #01	—	R 10 042	28d	—	—	—	—	—
BBD Variant #01	—	R 8 280	28d	—	—	—	—	—
BLD Variant #01	—	R 7 041	28d	—	—	—	—	—
Bortezomib and Dexamethasone (Vd) and Panobinostat Variant #01 Partial	—	R 6 925	21d	~12.0 mo	—	~18	~R 124 657 PFS proxy · indirect	1
Dara-Rd (SC daratumumab) Variant #01 Partial	—	R 5 792	28d	~38.0 mo	—	~42	~R 243 273 PFS proxy · indirect	2
ZRd Variant #01 Partial	—	R 5 792	28d	—	—	—	—	—
FRD Variant #01 Partial	—	R 5 705	28d	—	—	—	—	—
CPR Variant #01	—	R 5 606	28d	~20.0 mo	—	~22	~R 123 329 PFS proxy · indirect	2
SVd Variant #01 Partial	—	R 4 704	35d	~13.9 mo	—	~13	~R 61 148 PFS proxy · indirect	1
BVd Variant #01 Partial	—	R 4 617	21d	—	—	—	—	2
Dara-Vd (SC daratumumab) Variant #01 Partial	—	R 4 617	21d	—	—	—	—	1
CRd Variant #07	—	R 4 002	28d	—	—	—	—	—
Elo-Pd N/A - secondary systemic drug	—	R 0	28d	~7.4 mo	~29.8 mo	~9	~R 0 PFS proxy · indirect	3
Elo-Rd N/A - secondary systemic drug	—	R 0	28d	~19.4 mo	~48.3 mo	~22	~R 0 PFS proxy · indirect	2
Elo-Vd N/A - secondary systemic drug	—	R 0	—	~9.7 mo	—	—	—	2
PAD N/A - secondary systemic drug	—	R 0	28d	~35.0 mo	—	~39	~R 0 PFS proxy · indirect	2

39 of 39 regimens shown